Department of Oral and Maxillofacial Surgery, Linyi People's Hospital, Linyi, Shandong, 276003, China.
Department of Oral and Maxillofacial Surgery, Linyi People's Hospital, Linyi, Shandong, 276003, China.
Arch Oral Biol. 2018 May;89:20-25. doi: 10.1016/j.archoralbio.2018.01.016. Epub 2018 Jan 31.
MicroRNAs (miRs) have been shown to play critical roles in the pathogenesis of oral squamous cell carcinoma (OSCC), the current study is designed to identify the potential role of miR-186 in OSCC.
Realtime polymerase chain reaction was used to determine miR-186 expression in paired tissue samples (OSCC and adjacent normal tissues) and multiple oral cell lines (normal oral keratinocyte HOK cell and OSCC cell lines). Cell viability, colony formation and flow cytometry assays were used to assess the biological function of miR-186. Furthermore, luciferase and western blot assays were used to verify the predicted target of miR-186.
We found that miR-186 expression was significantly downregulated in OSCC tissues and cell lines. Overexpression of miR-186 produced an anti-growth effect and induced apoptosis in Tca8113 and SCC-25 cells. Luciferase assay revealed that miR-186 directly targeted PTPN11 (a gene encodes the protein tyrosine phosphatase SHP2) mRNA 3' untranslated region and suppressed its expression. Consistently, MiR-186 and SHP2 were negatively correlated in OSCC tissues. Consequently, miR-186 inhibited signaling activities of Extracellular Regulated protein Kinases (ERK) and Protein kinase B (AKT), which act downstream of SHP2 and are critical for growth of cancer cells.
We identify that miR-186 serves as a tumor suppressor in OSCC. Downregulation of this microRNA may lead to a higher expression of oncogenic factor SHP2, which leads to activation of growth promoting signaling. Thus, miR-186 may be a novel and effective therapeutic agent for the treatment of OSCC.
微小 RNA(miRs)已被证明在口腔鳞状细胞癌(OSCC)的发病机制中发挥关键作用,本研究旨在确定 miR-186 在 OSCC 中的潜在作用。
实时聚合酶链反应用于确定配对组织样本(OSCC 和相邻正常组织)和多个口腔细胞系(正常口腔角质形成细胞 HOK 细胞和 OSCC 细胞系)中 miR-186 的表达。细胞活力、集落形成和流式细胞术分析用于评估 miR-186 的生物学功能。此外,还使用荧光素酶和 Western blot 分析来验证 miR-186 的预测靶标。
我们发现 miR-186 在 OSCC 组织和细胞系中的表达明显下调。miR-186 的过表达在 Tca8113 和 SCC-25 细胞中产生了抗生长作用并诱导了细胞凋亡。荧光素酶测定显示,miR-186 直接靶向 PTPN11(编码蛋白酪氨酸磷酸酶 SHP2 的基因)mRNA 3'非翻译区并抑制其表达。一致地,miR-186 和 SHP2 在 OSCC 组织中呈负相关。因此,miR-186 抑制了 SHP2 下游的细胞外调节蛋白激酶(ERK)和蛋白激酶 B(AKT)信号通路的活性,这些信号通路对于癌细胞的生长至关重要。
我们发现 miR-186 在 OSCC 中作为肿瘤抑制因子发挥作用。这种 miRNA 的下调可能导致致癌因子 SHP2 的表达升高,从而导致促进生长的信号通路激活。因此,miR-186 可能是治疗 OSCC 的一种新的有效治疗剂。